NEW YORK – Scipher Medicine and Ambry Genetics said on Thursday that they have partnered to scale up the availability of Scipher's PrismRA blood-based molecular test to predict response to tumor necrosis factor inhibitor (TNFi) therapies in rheumatoid arthritis patients.